Who's Responsible for Cannabis Safety in Brazil?

Walk into a pharmacy in São Paulo and you will not find a cannabis dispensary. Brazil has no legal recreational market at all. What it does have is one of Latin America's largest medical cannabis systems, and it is run like any other prescription medicine: by the national health regulator, ANVISA.

So when a Brazilian patient picks up a bottle of cannabis oil, who actually made sure it is safe, correctly dosed, and free of contaminants? Here is the chain, from factory to prescription.

The short version: legal cannabis in Brazil is a pharmacy product. It needs an ANVISA sanitary authorization, it is made under pharmaceutical quality rules, and every batch is tested by a Brazil-accredited lab before it can be sold.

What you can actually buy

Only ANVISA-authorized "Cannabis products" reach pharmacy shelves, and only against a prescription. These are mostly CBD oils and full-spectrum extracts. More than two dozen products carry a full sanitary authorization today, and roughly 873,000 Brazilians were in treatment by the end of 2025.

Possessing a small amount for personal use is no longer a crime (Brazil's Supreme Court set that out in 2024, with 40 grams or six plants as the line between user and trafficker), but that is decriminalization, not a shop you can buy from. To buy legally, you go through a pharmacy, a personal-import authorization, or a court-authorized patient association.

Who checks that it is safe

Every legal product passes through a chain of licensed hands, and each one adds a layer of accountability:

The manufacturer or importer has to hold a company operating license (AFE) and a Good Manufacturing Practice certificate (CBPF) before it can touch the product.

ANVISA grants each individual product a sanitary authorization. That authorization number has to appear on the label, so anyone can tell the product cleared the regulator.

An accredited lab tests every batch and issues a Certificate of Analysis. Critically, this testing has to happen in Brazil, in a lab accredited to the national REBLAS network, even when the finished product was made abroad.

The pharmacy dispenses only the exact product named on the prescription, and keeps the record.

What "tested" actually means

The Certificate of Analysis is where safety stops being a promise and becomes a measurement. A Brazilian batch test covers:

Potency: the real THC and CBD content, measured by HPLC, so the strength on the label matches what is in the bottle.

Contaminants: heavy metals and pesticide residues.

Microbiology: screening for harmful bacteria and other pathogens.

Standard pharmaceutical checks on the physical product, such as density and consistency.

The label carries the rest of the safety story: the cannabinoid concentration, the ANVISA authorization number, the batch number, manufacture and expiry dates, a bold black band across the packaging, and a prescription warning. Products above 0.2% THC carry a stronger dependency warning and need a stricter prescription form.

The catch: the legal product is the controlled one

Brazil's system has a gap that doubles as its clearest safety lesson. Because pharmacy access is slow and expensive, thousands of patients grow at home under individual court orders (a "salvo-conduto"), or get oil through associations. Those routes are legal for the patient, but the product itself is not ANVISA-authorized, has no REBLAS batch test, and no standardized dose.

In other words, the safety controls live on the pharmacy product. The further you get from that shelf, the more you are trusting someone's word instead of a lab report.

That may be changing. In late 2024 Brazil's high court ordered ANVISA to regulate domestic cultivation of low-THC hemp for medicine, and in 2026 ANVISA published a new package of rules covering local production, research, and low-THC hemp cultivation. The direction is clear: pull more of the supply chain inside the tested, authorized system.

What it means for you

If you are ever offered a "medical" cannabis product in Brazil, the safety question is simple: does it have an ANVISA authorization number and a batch Certificate of Analysis? If yes, a regulator and a lab stand behind it. If no, you are the quality control.

Curious how this works where cannabis is sold recreationally? See our state-by-state walkthrough of who signs off on a US cannabis lab report at weed-central.com/learn/coa (https://weed-central.com/learn/coa?utm_source=newsletter.weed-central.com&utm_medium=newsletter&utm_campaign=who-s-responsible-for-cannabis-safety-in-brazil).

This article is general information, not legal or medical advice. Cannabis rules in Brazil are changing quickly; verify the current ANVISA requirements before relying on any detail.